Abstract
(Abstracted from BJOG 2021;128:504–514) Premalignant lesions such as cervical intraepithelial neoplasia (CIN) can develop into cervical cancer through a slow process taking up to 30 years from initial high-risk human papillomavirus (hrHPV) infection. Primary hrHPV DNA testing has superior sensitivity compared with cytology and has a high negative predictive value for high-grade CIN or worse (CIN2+).
Highlights
Persistent infection with a high-risk type of human papillomavirus is a necessary cause for cervical cancer.[1]
We will focus on methylation markers that have been clinically validated for the detection of cervical cancer, CIN3 and CIN2 in cervical scrapes and self-collected cervico-vaginal cells, and that are currently available within commercial or research methylation assays
BJOG: An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd on behalf of Royal College of Obstetricians and Gynaecologists in European countries, indicate that the referral rate could be lowered by approximately 34% by secondary triage of high-risk type of human papillomavirus (hrHPV)-positive women with ASC-US/LSIL cytology using FAM19A4/miR124-2 methylation, while still detecting all cervical carcinomas and at least 70% of CIN3 lesions (Bonde et al, submitted)
Summary
The use of host cell DNA methylation analysis in the detection and management of women with advanced cervical intraepithelial neoplasia: a review. This paper briefly reviews the role of hypermethylation of host cell genes in cervical carcinogenesis and discusses potential clinical applications of methylation analysis in the management of highrisk HPV (hrHPV) -positive women. For primary triage of hrHPV-positive women to detect cervical cancer and advanced cervical intraepithelial neoplasia (CIN); 2. Cervical intraepithelial neoplasia, DNA methylation, human papillomavirus. Tweetable abstract This paper discusses potential clinical applications of DNA methylation analysis in the management of women with a high-risk HPV infection.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
